American Capital Advisory LLC Purchases 614 Shares of Pfizer Inc. (NYSE:PFE)

American Capital Advisory LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 31.2% in the third quarter, Holdings Channel.com reports. The institutional investor owned 2,582 shares of the biopharmaceutical company’s stock after acquiring an additional 614 shares during the period. American Capital Advisory LLC’s holdings in Pfizer were worth $75,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Olistico Wealth LLC bought a new position in Pfizer during the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new position in Pfizer during the second quarter valued at approximately $29,000. Quarry LP bought a new position in Pfizer during the second quarter valued at approximately $31,000. Financial Connections Group Inc. bought a new position in Pfizer during the second quarter valued at approximately $34,000. Finally, ESL Trust Services LLC bought a new stake in shares of Pfizer in the 1st quarter valued at approximately $37,000. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent research reports. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. UBS Group lifted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Stock Down 2.4 %

NYSE PFE traded down $0.68 on Wednesday, reaching $27.31. 21,969,490 shares of the stock traded hands, compared to its average volume of 37,226,355. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The company has a fifty day moving average price of $28.99 and a 200-day moving average price of $28.65. The company has a market cap of $154.76 billion, a price-to-earnings ratio of 37.81, a PEG ratio of 0.89 and a beta of 0.67. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. Pfizer’s revenue was up 31.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.17) EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.15%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.